European Archives - Page 1307 of 1370 - European Medical Journal

Venetoclax (ABT-199/GDC-0199) plus rituximab shows promise in relapsed/refractory CLL

n a phase 1b, open-label, dose-escalation, multicentre study of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL), the combination…

Adding elotuzumab to standard treatment for myeloma reduced disease progression

ELOQUENT-2, a phase 3, randomised, open-label study of lenalidomide and dexamethasone with or without elotuzumab in patients with relapsed or refractory…

EMJ

Phase 3 CheckMate 067 trial of nivolumab in previously untreated advanced melanoma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, Consultant Medical Oncologist at The Royal Marsden…

EMJ

Whole Brain Radiation Therapy is More Harmful Than Beneficial for Small Brain Metastases

In the phase 3 NCCTG N0574 (Alliance) trial, patients with 1 to 3 small brain metastases were randomised to receive stereotactic radiosurgery (SRS) alone…

EMJ

Elective Neck Dissection Improved Survival in Early Node-Negative Oral Cancer

A phase 3, randomised controlled trial showed that elective neck dissection improved overall survival by 12.5% and reduced risk of death by 36% when…

EMJ

Improved Cancer Treatments Linked to Reduced Late Mortality in Childhood Cancer Survivors

Data from the Childhood Cancer Survivor Study (CCSS), a retrospective cohort study of children diagnosed with cancer from 1970–1999 at 31 participating…

EMJ

Combined Nivolumab and Ipilimumab or Monotherapy Shown Promise in Untreated Melanoma

The randomised, double-blind, phase 3 CheckMate 067 trial showed that nivolumab alone or nivolumab plus ipilimumab significantly improved progression…

EMJ

Novel JAK Inhibitor Pacritinib Proves Effective for Easing Symptoms of Myelofibrosis

Findings from the PERSIST-1 study of patients with myelofibrosis suggest that pacritinib is significantly more effective than best available therapy…

EMJ

Obinutuzumab Doubles Remission Duration in Relapsed, Indolent Non-Hodgkin Lymphoma

Interim analysis of a phase III study finds that adding the new anti-CD20 monoclonal antibody obinutuzumab to standard bendamustine chemotherapy…

EMJ

Daratumumab Shows Promise in Heavily Treatment-Resistant Multiple Myeloma

A phase II trial suggests that anti-CD38 antibody daratumumab is effective as a standalone therapy for heavily treated multiple myeloma. In a group of…